Glenmark Pharmaceuticals Ltd - Company Profile
Powered by 
All the data and insights you need on Glenmark Pharmaceuticals Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Glenmark Pharmaceuticals Ltd Strategy Report
- Understand Glenmark Pharmaceuticals Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Glenmark Pharmaceuticals Ltd patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| EP3110950B1 | Grant | EXPRESSIONSKONSTRUKTE UND VERFAHREN ZUR AUSWAHL VON POLYPEPTIDEXPRIMIERENDEN WIRTSZELLEN | C07K14/705; C07K16/00; C07K2317/31; C07K2317/52; C07K2317/622; C12N15/09; C12N15/1037; C12N15/85; C12N2830/42; C12N2830/50; C12P21/00; G01N33/56966; G01N33/6854 | September 21, 2022 |
| US20220273796A1 | Application | LYOPHILIZED ANTIBODY FORMULATION | A61K39/39591; A61K47/22; A61K47/26; A61K9/19; C07K16/2878; C07K2317/76 | September 01, 2022 |
| US20220257878A1 | Application | METERED DOSE INHALERS OF FLUTICASONE OR AN ESTER THEREOF | A61K31/56; A61K47/06; A61M15/002; A61M15/0068; A61M15/009; A61M2205/0238; A61M2209/045 | August 18, 2022 |
| US20220259209A1 | Application | PROCESS FOR THE PREPARATION OF ABROCITINIB | A61K9/146; C07B2200/13; C07D487/04 | August 18, 2022 |
| EP4041188A1 | Application | INHALIERBARE TROCKENPULVERZUSAMMENSETZUNG FÜR LUNGENERKRANKUNGEN | A61K31/4965; A61K47/26; A61K9/0075; A61P11/00; A61P11/06; C07D239/26 | August 17, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer